Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Abstract

CIS43LS was protective against <i>P. falciparum</i> infection over a 6-month malaria season in Mali without evident safety concerns. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04329104.).